This is especially true in the context of cancer, where DNA methylation appears as a key vulnerability of tumor cells, a lock that when lifted can induce cell-intrinsic toxic effects (162), as well as a greater responsiveness to immunotherapy (163); DNMT1, UHRF1 and both in combination are promising targets in this context (164). The gene discussed is UHRF1; the disease is cancer.